Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31417705 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ASIGMAR1LMNA | |
| SCHEMBL11888126 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ASIGMAR1LMNA | |
| SCHEMBL2251499 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ASIGMAR1LMNA | |
| SCHEMBL4829038 | 0.97 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ASIGMAR1LMNA | |
| SCHEMBL12359714 | 0.97 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ASIGMAR1LMNA | |
| SCHEMBL31565000 | 0.82 | ALDH1A1 (0.55) | ALDH1A1MEN1KMT2ASIGMAR1LMNA | |
| SCHEMBL20456548 | 0.82 | ALDH1A1 (0.55) | ALDH1A1MEN1KMT2ASIGMAR1LMNA | |
| SCHEMBL4395712 | 0.81 | PNMT (0.43) | ALDH1A1MEN1KMT2ALMNATHRA | |
| SCHEMBL4395713 | 0.81 | PNMT (0.43) | ALDH1A1MEN1KMT2ALMNATHRA | |
| SCHEMBL20456551 | 0.79 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2ASIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2479175-A1 | Compounds and methods for treating dyslipidemia | Eli Lilly and Company (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1761522-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2011-10-12 | — | — | EP | disclosed |
| US-7994333-B2 | Methods and compositions for selectin inhibition | WYETH LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994333-B2 | Methods and compositions for selectin inhibition | WYETH LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-7786108-B2 | Compounds and method for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7749992-B2 | Compounds and methods for treating dislipidemia | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1670768-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2098512-A1 | Compounds and methods for treating dyslipidemia | Eli Lilly & Company (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090069564-A1 | Methods and Compositions for Selectin Inhibition | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069564-A1 | Methods and Compositions for Selectin Inhibition | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-7465798-B2 | Methods and compositions for selectin inhibition | WYETH (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080125454-A1 | preventing selectin-mediated leukocyte adhesion to the vascular endothelium; 2-(4-Chloro-phenyl)-3-hydroxy-benzo[h]quinoline-4-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-h]quinoline-6-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-9-aza-cyclopenta[a]naphthale | WYETH (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125454-A1 | preventing selectin-mediated leukocyte adhesion to the vascular endothelium; 2-(4-Chloro-phenyl)-3-hydroxy-benzo[h]quinoline-4-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-h]quinoline-6-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-9-aza-cyclopenta[a]naphthale | WYETH (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2008043075-A2 | COMPOSITIONS FOR THE TREATMENT OF SCLERITIS | WYETH (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| EP-1761522-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| EP-1670768-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006002342-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005037796-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125454-A1 | preventing selectin-mediated leukocyte adhesion to the vascular endothelium; 2-(4-Chloro-phenyl)-3-hydroxy-benzo[h]quinoline-4-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-h]quinoline-6-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-9-aza-cyclopenta[a]naphthale | SELL, VCAM1, SELE | ALDH1A1 246/4885MEN1 4505/4885KMT2A 2985/4885 |
| US-20090069564-A1 | Methods and Compositions for Selectin Inhibition | SELP, SELE, SELL | ALDH1A1 285/4885MEN1 4598/4885KMT2A 4568/4885 |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | CETP, APOB, MTTP | ALDH1A1 4410/4885MEN1 3703/4885KMT2A 1760/4885 |
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | APOB, CETP, PCSK9 | ALDH1A1 2112/4885MEN1 1183/4885KMT2A 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.